000864921 001__ 864921
000864921 005__ 20210130002754.0
000864921 037__ $$aFZJ-2019-04524
000864921 1001_ $$0P:(DE-Juel1)167471$$aShymanskaya, Aliaksandra$$b0$$ufzj
000864921 1112_ $$aJahrestagung der Deutschen Gesellschaft für Nuklearmedizin 2019$$cBremen$$d2019-04-03 - 2019-04-06$$wGermany
000864921 245__ $$aComparison of [18F]-Fluoroethyltyrosine PET and the IDH status with Sodium MRI in Cerebral Gliomas
000864921 260__ $$c2019
000864921 3367_ $$0PUB:(DE-HGF)1$$2PUB:(DE-HGF)$$aAbstract$$babstract$$mabstract$$s1567774921_16307
000864921 3367_ $$033$$2EndNote$$aConference Paper
000864921 3367_ $$2BibTeX$$aINPROCEEDINGS
000864921 3367_ $$2DRIVER$$aconferenceObject
000864921 3367_ $$2DataCite$$aOutput Types/Conference Abstract
000864921 3367_ $$2ORCID$$aOTHER
000864921 520__ $$aV56Comparison of [18F]-Fluoroethyltyrosine PET and the IDH status with Sodium MRI in Cerebral GliomasA. Shymanskaya1, W. A. Worthoff1, G. Stoffels1, J. Lindemeyer1, B. Neumaier2, P. Lohmann1, N. Galldiks3, K. J. Langen1, N. J. Shah11Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine - 4, Jülich, Germany; 2Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine - 5, Jülich, Germany; 3Forschungszentrum Jülich GmbH, Institute of Neuroscience and Medicine - 3, Jülich, GermanyZiel/Aim:O-(2-[18F]fluoroethyl)-L-tyrosine([18F]-FET) PET is used for the supportive diagnostics of cerebral gliomas. In this study, the relationship between the [18F]-FET-PET parameters, distribution of restricted (mainly intracellular) and unrestricted (mainly extracellular) sodium, and the mutational status of the enzyme isocitrate dehydrogenase (IDH) were investigated in patients with cerebral gliomas.Methodik/Methods:Ten patients with untreated gliomas and one patient with a recurrent glioblastoma were investigated by dynamic [18F]-FET-PET and sodium MRI using an enhanced SISTINA sequence to estimate sodium parameters in tumours. The enhanced SISTINA sequence uses single-quantum and triple-quantum-filtered imaging and allows simultaneous acquisition of signal originating from restricted and unrestricted sodium (1). IDH mutational status was determined after biopsy or resection. The untreated patients were analysed independently in two groups (5 patients each) dependent on their IDH mutational status.Ergebnisse/Results:Tumour-to-brain ratio (TBR) of weighted mainly intracellular sodium (NaR) was significantly lower in IDH mutated (p=0.01) than in IDH wildtype gliomas. Total sodium concentration in mmol/L (p=0.05), TBR of the total sodium concentration (NaT) (p=0.02), TBR of weighted unrestricted mainly extracellular sodium (NaNR) (p=0.003), and the ratio of NaT/NaR (p<0.001) were significantly higher in IDH mutated than in IDH wildtype gliomas. [18F]-FET parameters estimated from tracer dynamics curves (TBR, time-to-peak) correlated neither to the IDH status nor to the sodium distribution. The patient with a recurrent GBM exhibited an additional radiation injury with strong abnormalities in sodium MRI.Schlussfolgerungen/Conclusions:Acquired results show that sodium MRI shows stronger relation to the IDH mutational status than [18F]-FET-PET parameters in cerebral gliomas in this patient cohort. Further evaluation of the combination of the three diagnostic modalities in gliomas seems promising and requires higher patient number.Literatur/References:[1] Worthoff WA, Shymanskaya A, Shah NJ. Relaxometry and quantification in simultaneously acquired single and triple quantum filtered sodium MRI. Magn Reson Med. 2018;00:1-13. doi:10.1002/mrm.27387.
000864921 536__ $$0G:(DE-HGF)POF3-572$$a572 - (Dys-)function and Plasticity (POF3-572)$$cPOF3-572$$fPOF III$$x0
000864921 7001_ $$0P:(DE-Juel1)156200$$aWorthoff, W. A.$$b1$$ufzj
000864921 7001_ $$0P:(DE-Juel1)131627$$aStoffels, G.$$b2$$ufzj
000864921 7001_ $$0P:(DE-Juel1)131657$$aLindemeyer, J.$$b3$$ufzj
000864921 7001_ $$0P:(DE-Juel1)166419$$aNeumaier, B.$$b4$$ufzj
000864921 7001_ $$0P:(DE-Juel1)145110$$aLohmann, P.$$b5$$ufzj
000864921 7001_ $$0P:(DE-Juel1)143792$$aGalldiks, N.$$b6$$ufzj
000864921 7001_ $$0P:(DE-Juel1)131777$$aLangen, K. J.$$b7$$ufzj
000864921 7001_ $$0P:(DE-Juel1)131794$$aShah, N. J.$$b8$$ufzj
000864921 8564_ $$uhttps://www.nuklearmedizin.de/jahrestagungen/abstr_online2019/abstract_detail.php?navId=227&aId=17
000864921 909CO $$ooai:juser.fz-juelich.de:864921$$pVDB
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)167471$$aForschungszentrum Jülich$$b0$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)156200$$aForschungszentrum Jülich$$b1$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131627$$aForschungszentrum Jülich$$b2$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131657$$aForschungszentrum Jülich$$b3$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)166419$$aForschungszentrum Jülich$$b4$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145110$$aForschungszentrum Jülich$$b5$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)143792$$aForschungszentrum Jülich$$b6$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131777$$aForschungszentrum Jülich$$b7$$kFZJ
000864921 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)131794$$aForschungszentrum Jülich$$b8$$kFZJ
000864921 9131_ $$0G:(DE-HGF)POF3-572$$1G:(DE-HGF)POF3-570$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lDecoding the Human Brain$$v(Dys-)function and Plasticity$$x0
000864921 9141_ $$y2019
000864921 920__ $$lyes
000864921 9201_ $$0I:(DE-Juel1)INM-3-20090406$$kINM-3$$lKognitive Neurowissenschaften$$x0
000864921 9201_ $$0I:(DE-Juel1)INM-4-20090406$$kINM-4$$lPhysik der Medizinischen Bildgebung$$x1
000864921 9201_ $$0I:(DE-Juel1)INM-5-20090406$$kINM-5$$lNuklearchemie$$x2
000864921 9201_ $$0I:(DE-Juel1)INM-11-20170113$$kINM-11$$lJara-Institut Quantum Information$$x3
000864921 980__ $$aabstract
000864921 980__ $$aVDB
000864921 980__ $$aI:(DE-Juel1)INM-3-20090406
000864921 980__ $$aI:(DE-Juel1)INM-4-20090406
000864921 980__ $$aI:(DE-Juel1)INM-5-20090406
000864921 980__ $$aI:(DE-Juel1)INM-11-20170113
000864921 980__ $$aUNRESTRICTED